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Abstract
Advanced glycation end products (AGEs) from the Maillard reaction contribute to protein aging and the pathogenesis of age-
and diabetes-associated complications. The a-dicarbonyl compound methylglyoxal (MG) is an important intermediate in AGE
synthesis. Recent studies suggest that pyridoxamine inhibits formation of advanced glycation and lipoxidation products. We wanted
to determine if pyridoxamine could inhibit MG-mediated Maillard reactions and thereby prevent AGE formation. When lens
proteins were incubated with MG at 37 C, pH 7.4, we found that pyridoxamine inhibits formation of methylglyoxal-derived AGEs
concentration dependently. Pyridoxamine reduces MG levels in red blood cells and plasma and blocks formation of methylglyoxal–
lysine dimer in plasma proteins from diabetic rats and it prevents pentosidine (an AGE derived from sugars) from forming in plasma
proteins. Pyridoxamine also decreases formation of protein carbonyls and thiobarbituric-acid-reactive substances in plasma proteins
from diabetic rats. Pyridoxamine treatment did not restore erythrocyte glutathione (which was reduced by almost half) in diabetic
animals, but it enhanced erythrocyte glyoxalase I activity. We isolated a major product of the reaction between MG and pyri-
doxamine and identified it as methylglyoxal–pyridoxamine dimer. Our studies show that pyridoxamine reduces oxidative stress and
AGE formation. We suspect that a direct interaction of pyridoxamine with MG partly accounts for AGE inhibition.  2002 Elsevier
Science (USA). All rights reserved.
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Protein amino groups combine with aldehydes and
ketones, in what is known as the Maillard reaction, to
produce advanced glycation end products or AGEs2
[1,2]. The reaction damages proteins by covalent cross-
linking and altering their conformation. AGEs accu-
mulate in tissues affected by diabetes and aging,
including the lens of the eye (cataract) [3], the aorta
(atherosclerosis) [4], and the brain (Alzheimer’s disease)
[5].
Although aldoses and ketoses were originally thought
to be the sole precursors of AGEs (thus providing the
name advanced glycation end products), recent studies
indicate that carbonyl compounds other than sugars are
even more reactive and that they produce AGE-like
products. Potential reactants include the a-dicarbonyls,
methylglyoxal (MG), and glyoxal. MG is produced
primarily by nonenzymatic pathways from glycolytic
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intermediates, such as glyceraldehyde 3-phosphate and
dihydroxyacetone phosphate and also by several minor
metabolic pathways, including the Maillard reaction [6].
Glyoxal is formed in the course of lipid peroxidation,
autoxidation of sugars, and by the Maillard reaction [7].
These two a-dicarbonyl compounds are extremely
reactive and readily modify lysine, arginine, and cysteine
residues on proteins.
Diabetic individuals have elevated levels of MG in
plasma and tissues [6], and Odani et al. reported that
uremic patients have significant increases in plasma
glyoxal [8]. Several studies identified dicarbonyl-derived
products in proteins from diabetic individuals; these
include imidazolium crosslinks, MOLD (imidazolysine)
(Fig. 1) [9–12], GOLD (glyoxal–lysine dimer) [13,14],
carboxyethyllysine [15], and argpyrimidine (Fig. 1)
[16,17].
In vitro incubation experiments showed that pyri-
doxamine (Fig. 1) can inhibit formation of AGEs [18,19]
and pyridoxamine also inhibits protein modifications by
lipid oxidation products [20]. The mechanism by which
pyridoxamine prevents AGE formation is still uncon-
firmed, although it is thought that pyridoxamine reacts
with dicarbonyl intermediates of AGE synthesis. Our
experiments show that pyridoxamine inhibits AGE
formation from MG both in vitro and in diabetic rats.
We also find that the production of methylglyoxal–
AGEs depends, in part, on formation of methylglyoxal–
pyridoxamine dimer (MOPD) (Fig. 1), an adduct of two
molecules of pyridoxamine and two molecules of MG.
Materials and methods
Bovine lenses were obtained from Pel-Freeze Bio-
logicals (Roger, AR). Pyridoxamine, methylglyoxal
(40% aqueous solution), and glyoxal (40% aqueous so-
lution) were from Sigma Chemical (St. Louis, MO). MG
Fig. 1. Structure of pyridoxamine, methylglyoxal–lysine dimer (MOLD) argpyrimidine and methylglyoxal–pyridoxamine dimer (MOPD).
R.H. Nagaraj et al. / Archives of Biochemistry and Biophysics 402 (2002) 110–119 111
was purified by vacuum distillation. All other chemicals
were of the highest high-performance liquid chromato-
graphy (HPLC) grade.
Extraction of bovine lens proteins. Bovine lenses were
decapsulated and homogenized in 50mM Tris buffer
(pH 7.4) (7.46 g/liter KCl, 0.37 g/liter EDTA, 0.35 g/liter
mercaptoethanol, 0.7 g/liter NaN3) using a glass
homogenizer. The homogenates were centrifuged for
30min at 10,000g, and the water-soluble supernatant
fraction was dialyzed against water for 24 h, concen-
trated, lyophilized, and stored at )80 C.
Incubation of bovine lens proteins with MG and pyri-
doxamine. We incubated bovine lens proteins (BLP)
(30mg/ml) with 5 or 50mM MG in the presence or ab-
sence of pyridoxamine. Incubations with BLP alone were
done simultaneously as controls. Pyridoxamine was ad-
ded to both sets at three different concentrations (5, 15, or
50mM) to make a total volume of 3.0ml. All incubations
were done in 0.2M phosphate buffer (pH 7.4) at 37 C.
Aliquotswere drawnafter 0, 15, and 30 days of incubation
and dialyzed against 2.0 l of PBS for 48 h. Samples con-
taining 50mM pyridoxamine and 50mMMG developed
precipitate after 15 days of incubation. These reaction
mixtures were centrifuged, and protein concentration in
the supernatant was measured and used for assays.
Animal experiments. All experimental procedures in-
volving animals were designed to conform to the ARVO
Statement for the Use of Animals in Ophthalmic and
Vision Research and the guidelines of the Animal Re-
sources Center of the Case Western Reserve University
(Cleveland, OH). Sprague–Dawley rats (3 months old,
approximately 150 g) were made diabetic by a single
intraperitoneal injection of streptozotocin (65mg/kg
body wt in citrate buffer). Development of diabetes was
confirmed by the appearance of glycosuria and hyper-
glycemia. All animals used in this study had <250mg=dl
plasma glucose. Nondiabetic animals of comparable age
and weight were maintained as controls (C). Each group
had at least 12 animals. Pyridoxamine was administered
by dissolving it in the drinking water. Diabetic animals
received 400mg/dl (D+PM) and nondiabetic animals
received 800mg/dl (C+PM). The dosage was lower in
diabetic animals to compensate for higher water intake
when compared to nondiabetic control animals (D). The
animals had access to water throughout the day and
were maintained for 21 weeks, after which they were
killed with a high dose of pentobarbital. Blood was
drawn from heart immediately after death; plasma and
blood cells were then separated by centrifugation.
Preparation of erythrocyte and plasma proteins. Ery-
throcytes were lysed in distilled water and centrifuged at
4000 rpm in an Eppendorf microcentrifuge for 10min at
4 C to remove the membranes. The supernatant frac-
tion was mixed with an equal volume of 10% trichlo-
roacetic acid (TCA) to precipitate the proteins. Plasma
samples were similarly treated with 10% TCA. The
precipitated proteins were washed twice with diethyle-
ther, dried under vacuum, and then suspended in 1.0ml
of water and lyophilized to a powder. All protein
preparations were stored at 20 C until use.
HPLC assays for AGEs. We identified and measured
the imidazolium crosslink, MOLD, by a two-step HPLC
assay [21]. Argpyrimidine and pentosidine were mea-
sured by HPLC as described by Wilker et al. [22].
Characterization of major reaction product of pyri-
doxamine and methylglyoxal. MG and pyridoxamine
(0.1M each) were mixed together in 100mM phosphate
buffer (pH 7.4) and incubated at 37 C for 24 h. HPLC
analysis of the incubation (HPLC conditions below)
indicated the presence of unreacted pyridoxamine.
When two more equivalents of MG were added, and the
incubation was extended for an additional 48 h, nearly
all of the pyridoxamine was reacted; the products, ob-
tained under these conditions, were then applied to
purification. HPLC of the reactants from the pyridox-
amine +MG incubation was performed on a semipre-
parative reverse-phase column (C18, 10lm, Separations
Group, Vydac, Hesperia, CA). The mobile phase con-
sisted of solvent A (0.01M HFBA in water) and solvent
B (40% water in acetonitrile with 0.01M HFBA). The
gradient was as follows: 0–3min, 0% B; 3–15min, 50%
B; 15–25min, 50% B; 25–30min, 100% B; 30–33min,
100% B; 33–45min 0% B. The flow rate was 2.0ml/min.
The column effluent was monitored for absorption at
325 nm, and we found that pyridoxamine eluted at ap-
proximately 18min. We noted a major peak at 31min;
this was collected from repeated injections, pooled, and
lyophilized.
We then subjected the lyophilized product to NMR
and mass spectrometry. 1H (300MHz), 13C (75.4MHz),
double-quantum-filtered COSY (DQFCOSY) [23]
heteronuclear single quantum coherence (HSQC), and
heteronuclear multiple bond correlation (HMBC) NMR
spectra were recorded on a Varian Unity Inova 300
spectrometer (Darmstadt, Germany) in D2O. Chemical
shifts ðdÞ are given in ppm relative to external sodium
2,2,3,3-tetradeutero-3-(trimethylsilyl)propanoate and
coupling constants (J) in Hz.
We used aMicromass (Manchester, UK) VGplatform
II quadrupole mass spectrometer equipped with an ESI
interface for accurate mass determination [24]. Mass
spectrometry parameters were ESI+, source temperature
80 C, capillary 3.0 kV,HV lens 0.5 kV, cone voltage 35V.
The data were collected in the multichannel acquisition
mode with 128 channels perm/z unit using nine scans (6 s)
with 0.1-s reset time. The resolution was 960 (10% valley
definition). The sample was dissolved for analysis in wa-
ter/acetonitrile (1/1) containing polyethylene glycol 400
ð0:1lg=llÞ as reference material, ammonium formate
(0.2%), and formic acid (1%); the sample concentration
was similar to that of polyethylene glycol. The solu-
tion was introduced into the ESI source at a flow
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rate of 5ll=min. We calibrated six reference peaks
with m/z 325–435 scan range: m/z 327.2019, 344.2284,
371.2281, 388.2547, 415.2543, 432.2809. From these data
we assigned the structure to be 1,3-bis{[3-hydroxy-5-
(hydroxymethyl)-2-methyl-4-pyridinyl]methyl}-4-methyl-
imidazolium, methylglyoxal pyridoxamine dimer.
Detection of methylglyoxal pyridoxamine dimer
(MOPD) in protein incubation. Bovine serum albumin
(10mg/ml) was incubated with 25mM each of MG and
pyridoxamine at 37 C in 3.0ml of 50mM phosphate
buffer (pH 7.4). Samples (0.05ml) were drawn after 0, 1,
3, 5, and 7 days of incubation. The protein was precip-
itated by addition of 0.5ml of 10% trichloroacetic acid.
Pyridoxamine and MOPD were measured in the tri-
chloroacetic acid supernatant by HPLC using a C-18
reverse-phase analytical column (Vydac). HPLC condi-
tions were the same as described for purification of
methylglyoxal pyridoxamine dimer, except that the flow
rate was 1.0ml/min. Under these conditions, pyridox-
amine eluted at 18.6min and MOPD at 33.6min.
Other methods. Glycated hemoglobin was measured
by a kit (Sigma total glycated hemoglobin kit, Cat. No.
442-B) according to the manufacturer’s instructions.
MG was measured as described by Shamsi et al. [25].
Glyoxalase I activity was measured in erythrocyte ly-
sates as described by Haik et al. [26]. Plasma protein
carbonyl content was measured by the method of Oliver
et al. [27]. GSH levels in erythrocytes were measured by
the method of D’Aquino et al. [28]. Thiobarbituric-acid-
reactive substances (TBARS) in plasma proteins were
measured by the method of Kakkar et al. [29]. Protein
was quantified with a Bio-Rad kit using bovine serum
albumin as the standard. Amino acid content of acid
hydrolyzates was determined by the ninhydrin reaction
method [30].
Results
To determine how pyridoxamine affects methylgly-
oxal-mediated AGE synthesis, we used HPLC to mea-
sure MOLD, the imidazolium lysine–lysine crosslinking
structure, in samples of bovine lens proteins that were
incubated for 30 days. Incubation for 30 days were
performed to determine if intermolecular crosslinking,
which occurs as a result of advanced glycation end
product formation, is affected in the presence of pyri-
doxamine. We were unable to measure MOLD at the
earlier time periods (0 and 15 days) because of the low
levels of product in those incubation samples. Fig. 2A
shows that 50mM pyridoxamine inhibited MOLD for-
mation by nearly 80% when bovine lens proteins were
incubated with 5mM MG. However, inhibition was less
impressive in samples exposed to 50mM MG; here the
Fig. 2. (A) Effect of pyridoxamine on MOLD formation. Bovine lens proteins were incubated in vitro with MG (5mM) in the presence of 0, 5, 15, or
50mM pyridoxamine for 30 days and MOLD was measured by HPLC of the acid-hydrolyzed protein. Values indicated by bars are the average of
two determinations. (B) Bovine lens proteins were incubated under the same conditions with 50mM MG and varying concentrations of pyridox-
amine.
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same concentration of pyridoxamine (50mM) inhibited
MOLD formation by approximately 45% (Fig. 2B). We
concluded that under these conditions, pyridoxamine
inhibits MOLD formation more effectively at the lower
MG concentration. SDS–polyacrylamide gel electro-
phoresis of the incubated samples revealed that pyri-
doxamine (at 50mM concentration) partly inhibited
MG-induced protein crosslinking (data not shown).
Table 1 shows body weights and biochemical pa-
rameters in control and diabetic animals at the end of
the study. Mean blood glucose was five to six times
higher in diabetic animals (D) than in control animals
(C). Treatment with pyridoxamine slightly improved
glycemia in diabetic animals (D+PM) and slightly in-
hibited the loss in body weight from untreated diabetes.
Glycated hemoglobin levels were three to four times
higher in diabetic animals, and there was a slight trend
toward further elevations in pyridoxamine-treated dia-
betic animals.
Fig. 3 shows that MG levels were approximately 10–
15 times higher in plasma (Fig. 3A) than in erythrocytes
(Fig. 3B). In diabetic animals, MG levels increased in
both erythrocytes and plasma, but the increase was
significant ðP < 0:05Þ only in plasma. Pyridoxamine
treatment did not alter MG levels in nondiabetic rats
(C+PM), but in both fractions from diabetic rats, it
significantly reduced MG levels ðP < 0:05Þ. Surpris-
ingly, MG levels were lower in pyridoxamine-treated
diabetic rats (D+PM) when compared to control rats.
To determine if pyridoxamine affected glyoxalase I
activity, we measured the enzyme activity in erythro-
cytes from diabetic and control animals. Cell lysates
were dialyzed against PBS before assay, thereby ex-
cluding the effect of endogenous MG and glutathione.
Glutathione is essential for the metabolism of MG
through glyoxalase. Glutathione reacts nonenzymati-
cally with MG to form a hemithioacetal complex, which
is a substrate for glyoxalase I. The product of the gly-
oxalase I reaction, S-D-lactoylglutathione, is then con-
verted to D-lactate by glyoxalase II. We found
significant reduction of glutathione levels in lysed ery-
throcyte preparations from diabetic animals, but pyri-
doxamine treatment in vivo did not alter this
phenomenon (Fig. 4A). As shown in Fig. 4B, glyoxalase
I activity was unchanged in diabetes, but we found a
significant increase in activity in erythrocytes from
pyridoxamine-treated diabetic rats (D+PM). These
data suggest that pyridoxamine increases the glyoxalase
I activity under the hyperglycemic conditions.
To determine if pyridoxamine affects methylglyoxal-
mediated Maillard reactions in diabetes, we measured
MOLD in plasma proteins. There was a trend towards
increased MOLD levels in diabetes; mean levels were
approximately 20% higher in plasma proteins from
Table 1
Physical and biochemical parameters of animals in treatment groups




Body weight (g) 628 60 299 59 552 52 340 81
Blood glucose (mg/dl) 76 9 413 39 69 5 375 62
Glycated hemoglobin (%) 5:23 1:07 14:39 1:43 5:46 0:74 17:85 3:78
Note. C, control nondiabetic rats; D, diabetic; C+pyridoxamine, nondiabetic rats treated with 0.8 g/liter pyridoxamine; D+pyridoxamine,
diabetic rats treated with 0.4 g/liter pyridoxamine.
Fig. 3. MG in plasma (A) and erythrocytes (B) from control (C) and
diabetic (D) rats and those treated with pyridoxamine. MG was
measured by HPLC. The heights of the bars indicate MG concentra-
tions (nmol/ml). Bars that do not share a common superscript are
statistically significant ðP < 0:05Þ.
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diabetic animals than in those from controls, but the
differences were not significant (Fig. 5). Pyridoxamine
treatment caused a trend toward increased MOLD in
nondiabetic animals, but in diabetic animals it reduced
MOLD levels by nearly 40% ðP < 0:05Þ.
We also used HPLC to measure argpyrimidine, an-
other methylglyoxal-derived AGE in plasma proteins.
Our HPLC chromatogram showed a peak that had
identical retention time to that of synthetic argpyrimi-
dine (data not shown). The material in this peak was
quantified based on a standard curve generated by in-
jecting several concentrations of synthetic argpyrimi-
dine. Mass spectrometric analysis is necessary to further
confirm argpyrimidine in this peak. Our results showed
that mean ‘‘argpyrimidine’’ levels were higher in diabetic
rats (5:9 0:2pmol=mmol of amino acids) compared to
nondiabetic controls ð4:2 0:2Þ, but the increase was
not statistically significant. Pyridoxamine treatment of
diabetic rats reduced the levels to control levels
ð4:3 0:3Þ. Pyridoxamine treatment in nondiabetic rats
had no effect on argpyrimidine levels ð4:0 0:1Þ.
Fig. 6 shows accumulation of pentosidine in plasma
proteins from diabetic rats. The samples from untreated
diabetic rats had nearly 30% higher concentrations of
pentosidine ðP < 0:05Þ than those from controls. Pyri-
doxamine suppressed this increase, reducing the mean
value to nearly 17% less than that for the pyridoxamine-
treated control group.
We reasoned that the beneficial effects of pyridox-
amine on AGE formation might be due to a reduction of
oxidative stress. To test this possibility we measured
TBARS and protein carbonyl content, since both of
these parameters increase with oxidative stress. As can
Fig. 4. Effect of pyridoxamine on glutathione and glyoxalase I in
erythrocytes. Rats were treated with pyridoxamine in drinking water
for 5 months. (A) Glutathione concentrations (nmol/ml) in control (C)
and diabetic (D) animals. Pyridoxamine was administered to both
groups in drinking water (0.8 g/liter (C+PM) or 0.4 g/liter (D+PM).
(B) Glyoxalase I activity for the same treatment groups. Statistical
determination as in Fig. 3.
Fig. 5. Effect of pyridoxamine treatment on plasma protein MOLD.
Samples were acid hydrolyzed and separated on a C-18 column, and
fractions corresponding to MOLD were collected, derivatized with
PITC, and separated by C-18 HPLC.
Fig. 6. Effect of pyridoxamine on plasma protein pentosidine. Control
and diabetic rats were treated with pyridoxamine in vivo as described
in the legend to Fig. 4. Statistical determination as in Fig. 3.
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be seen in Fig. 7A and B, both TBARS and protein
carbonyl content increased in samples from diabetic
animals relative to controls. The increase in TBARS was
significant ðP < 0:05Þ, and pyridoxamine treatment
suppressed this increase by nearly 22% (Fig. 7A). Plas-
ma proteins from diabetic rats had more protein car-
bonyls (by approximately 30%) than those from
nondiabetic controls (Fig. 7B). Surprisingly, pyridox-
amine treatment decreased protein carbonyls in the di-
abetic group well below the comparable controls; this
did not occur in nondiabetic animals.
To determine if the inhibition of MOLD formation
by pyridoxamine was due to a direct reaction of MG
with pyridoxamine, we incubated MG with pyridox-
amine in vitro using conditions that closely approximate
those in vivo. We injected this sample into the HPLC
column and monitored the effluent at 325 nm. We found
one major peak and several minor peaks. We purified
the major peak by preparative HPLC and reexamined
the product by spectroscopy. When this product was
reinjected into the same column using the same gradient
system, we obtained a single peak (Fig. 8A) that was
more hydrophobic than pyridoxamine (retention time
18.6min) (Fig. 8B). The spectrum of the purified com-
pound was nearly identical to that of pyridoxamine;
both show absorption maxima at approximately 325 nm
(data not shown).
Table 2 shows chemical shifts from 1H NMR and 13C
NMR spectra. Our isolated product contains two pyri-
doxamine residues, as indicated by the signal for two
methyl groups of the pyridoxamine moieties at d 2.55
showing a 6H integral. The methyl group on the imi-
dazolium ring shows a chemical shift of d 2.16. 13C
Fig. 7. Pyridoxamine effect on TBARS and protein carbonyl in plasma
proteins. (A) TBARS (pmol/ml) in plasma proteins from control and
diabetic rats following in vivo treatment with pyridoxamine. (B)
Pyridoxamine effect on protein carbonyl content (nmol/mg protein).
Statistical determination as in Fig. 3.
Fig. 8. HPLC of pyridoxamine+MG incubation. Reverse-phase
HPLC showed a major absorbance product at 325 nm. This product
was collected from several injections and reinjected onto the same
column. (A) The chromatogram for the purified product and (B) the
chromatogram for pyridoxamine.
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NMR displays 20 carbon atoms. Hydrogen and carbon
assignments were validated by DQFCOSY, HSQC, and
HMBC. The accurate mass (mean SD from 10 mea-
surements) was determined to be m/z 385. 1882 0:0006
½MþHþ. The m/z of 385.1876 corresponded to the
empirical formula C20H25N4O4. From these data we
assigned the structure of the compound as 1,3-bis{[3-
hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]meth-
yl}-4-methylimidazolium (Table 2). We designated
MOPD as the abbreviation for this structure.
Finally, when we incubated BSA with MG and
pyridoxamine, we found that the time-dependent in-
crease in methylglyoxal–pyridoxamine dimer coincided
with a decrease in pyridoxamine (Fig. 9). This suggests
that inhibition of the MG-mediated reaction by
pyridoxamine is related to formation of methylglyoxal–
pyridoxamine dimer. Since we now believe that meth-
ylglyoxal–pyridoxamine dimer is an important product
of MG and pyridoxamine, our data indicate that the
inhibitory effects of pyridoxamine are due to its inter-
action with MG.
Discussion
Booth et al. were the first investigators to report that
pyridoxamine could block post-Amadori reactions that
lead to AGEs [31]. They found that pyridoxamine
inhibited AGE formation in samples of bovine serum
albumin incubated with glucose and noted that it was a
more effective inhibitor than aminoguanidine. Baynes
and colleagues reported that pyridoxamine inhibited
advanced glycation and lipoxidation end products and
suggested that some of the beneficial effects of pyri-
doxamine were due to this mechanism [20]. The same
authors recently showed that pyridoxamine treatment
prevents development of pathological changes associ-
ated with renal functions in diabetic rats [32].
Although it is not clear exactly how pyridoxamine
inhibits AGE formation, one possibility is that it acts
through nucleophilic reactions with carbonyl interme-
diates of the Maillard reaction. A recent study by Vo-
ziyan et al. [33] showed that pyridoxamine reacts
directly with Maillard reaction intermediates glyoxal
and glycoaldehyde and inhibits formation of carbo-
xylmethyllysine. Because we wanted to determine if the
beneficial effects of pyridoxamine were due, in part, to
inhibition of MG-mediated reactions, we used diabetic
rats. These animals provided a metabolic model of en-
hanced AGE formation in vivo, in which, over 5 months
of treatment, we were able to determine how pyridox-
amine affects specific products of the reaction of proteins
with MG.
Our in vitro experiments with plasma proteins
showed that pyridoxamine was an ineffective inhibitor of
MOLD formation at a pyridoxamine:MG ratio of 1:1
(Fig. 2). However, when the ratio of pyridoxamine:MG
was 10:1, MOLD formation was inhibited by 80%. This
finding suggests that MG reacts to a greater extent with
proteins than with pyridoxamine. In this regard, De-
genhardt et al. [34] described steady-state levels of
pyridoxamine that can reach 100lM in diabetic rats
Table 2
Chemical shifts for the purified product
No. 1H 13C




4-CH3 2.16 (3H, d,
J ¼ 0:8HzÞ
11.16
5 7.19 (1H, m) 122.28




40-CH3 2.55 (3H) 17.86
50 8.14 (1H) 134.44
60 140.84
60-CH2OH 4.73 (2H) 61.26




400-CH3 2.55 (3H) 17.86
500 8.19 (1H) 134.36
600 140.98
600-CH2OH 4.72 (2H) 61.31
Note. Chemical shift ðdÞ is expressed in ppm relative to external
standard, sodium 2,2,3,3-tetradeutero-3-(trimethylsilyl)propionate.
Coupling constant ðJÞ is expressed in Hz. s, singlet; d, doublet; m,
multiplet. See Fig. 1 for structure.
Fig. 9. MOPD formation and MG utilization of pyridoxamine. Bovine
serum albumin was incubated in vitro with MG and pyridoxamine,
and MOPD and pyridoxamine were measured by HPLC in superna-
tant samples. The time-dependent increase in methylglyoxal–pyridox-
amine dimer mirrors the decrease in pyridoxamine in the incubation
medium.
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treated with 1 g/liter of pyridoxamine. We used a lower
dose (0.4 g/liter) to treat our diabetic animals, but as-
suming that a proportionately lower steady-state level of
pyridoxamine occurs, our animals should have plasma
concentrations of pyridoxamine around 40lM. Since we
found plasma MG levels to be approximately 5lM,
40lM pyridoxamine would be sufficient to react with all
the plasma MG.
We were surprised to find that MOLD levels in
pyridoxamine-treated diabetic rats were 30–35% lower
than in nondiabetic controls and nondiabetic + pyri-
doxamine rats (Fig. 5). One possible explanation is that,
because of increased cellular permeability in diabetes,
pyridoxamine binds to MG within the cells, thus pre-
venting leakage of MG into plasma. Our data on ery-
throcyte MG levels support this (Fig. 3). We find that
MG concentrations are significantly lower in pyridox-
amine-treated diabetic rats than in untreated diabetic or
nondiabetic, pyridoxamine-treated animals. MG levels
in plasma proteins did not correlate with the levels of
plasma protein–MOLD. MOLD was not significantly
elevated in samples from diabetic rats, but pyridoxamine
treatment did reduce it in the diabetic group relative to
controls.
It should be noted that MG reacts with proteins to
produce a variety of other compounds in addition to
MOLD and argpyrimidine. For example, other products
of MG-protein reactions include N 5-(4-methyl-5-oxo-
4,5-dihydro-1H-imidazol-2-yl)ornithine [35] and N6-
carboxyethyllsyine [36]. In order to understand how
pyridoxamine influences all the various methylglyoxal-
mediated modifications, we would need methods to
measure all of the diverse AGEs that result from MG–
protein interactions. Pending availability of such meth-
ods, we can only speculate that pyridoxamine inhibits
other modifications by MG in addition to the ones we
observed.
The glyoxalase enzyme system is important for the
detoxification of MG in cells [6]. Glyoxalase I, the first
of two enzymes, converts the hemithioacetal formed
from the nonenzymatic reaction of MG and GSH to
D-S-lactoylglutathione. Glyoxalase II then converts this
product to D-lactate. We measured glyoxalase I activity
in the dialyzed proteins from erythrocytes and found
that glyoxalase I activity was unaltered in diabetic rats
(Fig. 4B). This result confirmed observations from a
previous study, but we were surprised to find that dia-
betic animals treated with pyridoxamine had higher
enzyme activity than other treatment groups. This sug-
gests that pyridoxamine either induces synthesis of gly-
oxalase I or activates native erythrocyte glyoxalase I.
Increased erythrocyte glyoxalase I activity may ac-
count for decreased MG concentrations in diabetic an-
imals treated with pyridoxamine. Glutathione levels
were not significantly altered by pyridoxamine treat-
ment, but glutathione was significantly lower in both
pyridoxamine-treated and untreated diabetic animals
compared to nondiabetic controls (Fig. 4A). Whether
the diabetic animals had sufficient glutathione to sup-
port the observed increase in glyoxalase I activity re-
mains to be determined.
We recorded significantly elevated levels of pentosi-
dine in diabetic rats and found that pyridoxamine
treatment suppressed formation of this product (Fig. 6).
Like MOLD, the pentosidine levels were less in pyri-
doxamine-treated diabetic rats than either untreated or
nondiabetic controls. This finding supports our idea that
pyridoxamine probably prevents pentosidine precursors
from forming at their sites of origin. This might occur at
selected sites in cell metabolism., e.g., the formation of
ribose or oxidation of ascorbate. In fact, a recent study
indicates that pyridoxamine inhibits degradation of
ascorbate [37] by binding to metal ions. Another recent
study suggests that pyridoxamine inhibits formation of
oxygen free radicals and lipid oxidation [38]. These ef-
fects may reduce synthesis of AGEs.
Inhibition of MG-mediated Maillard reactions by
pyridoxamine, at least in part, appears to be due to
formation of MOPD a compound that we identified by
spectroscopic methods. Methylglyoxal pyridoxamine
dimer is similar in structure to MOLD [9,11], the dif-
ference being that there are two pyridoxamine molecules
in place of two lysines. The ability of pyridoxamine to
sequester MG before it reacts with lysines and arginines
of target proteins depends upon several factors, includ-
ing the relative reactivity of MG with pyridoxamine, the
reactivity with lysine and arginine and the concentration
of reactants. The inhibition of MOLD formation ob-
served in our incubation experiments suggests that
pyridoxamine prevents protein crosslinking by MG.
Further experiments with our animal models should
clarify the mechanism. Incubation of bovine serum al-
bumin with MG in the presence of pyridoxamine
showed a time-dependent increase in the formation of
methylglyoxal pyridoxamine dimer that correlated with
the disappearance of pyridoxamine (Fig. 9). Thus,
MOPD formation appears to be a mechanism by which
pyridoxamine protects against MG-mediated reactions.
In summary, our study establishes that pyridoxamine
inhibits formation of AGEs by preventing dicarbonyl-
mediated reactions. Whether this inhibition occurs
through direct reaction of a-dicarbonyls with pyridox-
amine or by inhibition of pathways that enable a-di-
carbonyls to react with proteins remains to be
established.
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